TY - JOUR
T1 - Erythropoietin receptor positive circulating progenitor cells and endothelial progenitor cells in patients with different stages of diabetic retinopathy
AU - Hu, Liu Mei
AU - Lei, Xia
AU - Ma, Bo
AU - Zhang, Yu
AU - Yan, Yan
AU - Wu, Ya Lan
AU - Xu, Ge Zhi
AU - Ye, Wen
AU - Wang, Ling
AU - Xu, Guo Xu
AU - Xu, Guo Tong
AU - Li, Wei Ye
N1 - Funding Information:
1Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China 2Tongji Eye Institute and Department of Regenerative Medicine, Tongji University School of Medicine, Shanghai 200092, China 3Laboratory of Clinical Visual Sciences, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China 4Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai 200031, China 5Department of Ophthalmology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China 6Department of Ophthalmology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China 7Department of Ophthalmology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China 8Department of Ophthalmology, Drexel University College of Medicine, Philadelphia, PA 19107, USA
PY - 2011/6
Y1 - 2011/6
N2 - To investigate the possible involvement of erythropoietin (EPO)/erythropoietin receptor (EPOR) system in neovascularization and vascular regeneration in diabetic retinopathy (DR). EPOR positive circulating progenitor cells (CPCs: CD34+) and endothelial progenitor cells (EPCs: CD34 +KDR+) were assessed by flow cytometry in type 2 diabetic patients with different stages of DR. The cohort consisted of age- and sex-matched control patients without diabetes (n=7), non-proliferative DR (NPDR, n=7), proliferative DR (PDR, n=8), and PDR complicated with diabetic nephropathy (PDR-DN, n=7). The numbers of EPOR+ CPCs and EPOR + EPCs were reduced remarkably in NPDR compared with the control group (both P<0.01), whereas rebounded in PDR and PDR-DN groups in varying degrees. Similar changes were observed in respect of the proportion of EPOR + CPCs in CPCs (NPDR vs. control, P<0.01) and that of EPOR + EPCs in EPCs (NPDR vs. control, P<0.05). Exogenous EPO, mediated via the EPO/EPOR system of EPCs, may alleviate the impaired vascular regeneration in NPDR, whereas it might aggravate retinal neovascularization in PDR due to a rebound of EPOR+ EPCs associated with ischemia.
AB - To investigate the possible involvement of erythropoietin (EPO)/erythropoietin receptor (EPOR) system in neovascularization and vascular regeneration in diabetic retinopathy (DR). EPOR positive circulating progenitor cells (CPCs: CD34+) and endothelial progenitor cells (EPCs: CD34 +KDR+) were assessed by flow cytometry in type 2 diabetic patients with different stages of DR. The cohort consisted of age- and sex-matched control patients without diabetes (n=7), non-proliferative DR (NPDR, n=7), proliferative DR (PDR, n=8), and PDR complicated with diabetic nephropathy (PDR-DN, n=7). The numbers of EPOR+ CPCs and EPOR + EPCs were reduced remarkably in NPDR compared with the control group (both P<0.01), whereas rebounded in PDR and PDR-DN groups in varying degrees. Similar changes were observed in respect of the proportion of EPOR + CPCs in CPCs (NPDR vs. control, P<0.01) and that of EPOR + EPCs in EPCs (NPDR vs. control, P<0.05). Exogenous EPO, mediated via the EPO/EPOR system of EPCs, may alleviate the impaired vascular regeneration in NPDR, whereas it might aggravate retinal neovascularization in PDR due to a rebound of EPOR+ EPCs associated with ischemia.
KW - circulating progenitor cells
KW - diabetic retinopathy
KW - endothelial progenitor cells
KW - erythropoietin receptor
UR - http://www.scopus.com/inward/record.url?scp=79961116472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79961116472&partnerID=8YFLogxK
U2 - 10.1016/S1001-9294(11)60023-0
DO - 10.1016/S1001-9294(11)60023-0
M3 - Article
C2 - 21703113
AN - SCOPUS:79961116472
SN - 1001-9294
VL - 26
SP - 69
EP - 76
JO - Chinese Medical Sciences Journal
JF - Chinese Medical Sciences Journal
IS - 2
ER -